Promoted Content
Promoted Content

Find Oncology Drugs in Phase I Clinical Development in CHINA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GC007g

            Therapeutic Area: Oncology Product Name: GC007g

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2021

            Details:

            The seamless Phase 1/2 pivotal clinical trial of GC007g will enable Gracell to potentially substantially accelerate the clinical development of GC007g in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GC012F

            Therapeutic Area: Oncology Product Name: GC012F

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Jefferies

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering December 18, 2020

            Details:

            Gracell's lead FasTCAR-enabled candidate, GC012F, has achieved multiple minimal residual disease, negative stringent complete responses in relapsed or refractory multiple myeloma patients in an ongoing investigator-initiated Phase 1 trial in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha,Paclitaxel

            Therapeutic Area: Oncology Product Name: IMP321

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Immutep

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 10, 2020

            Details:

            EOC Pharma trial will be a randomised, double-blind, placebo controlled phase II clinical study to evaluate its lead product candidate eftilagimod alpha in combination with paclitaxel in HER2-/HR+ metastatic breast cancer patients who have progression after endocrine therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lemzoparlimab

            Therapeutic Area: Oncology Product Name: TJC4

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            The purpose of the call is to provide an expanded analysis of the clinical efficacy signal from the U.S. phase 1 clinical trial of Lemzoparlimab (also known as TJC4), which is not previously discussed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Letaplimab,Rituximab

            Therapeutic Area: Oncology Product Name: IBI188

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 11, 2020

            Details:

            The phase 1a clinical study is evaluating the tolerability, safety, and PK/PD properties of IBI188 (letaplimab) as monotherapy for advanced malignancies that failed in standard treatments. With a total of over 60 subjects enrolled, letaplimab was well tolerated generally.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CTA101

            Therapeutic Area: Oncology Product Name: CTA101

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            Details:

            The data will be presented regarding the pre-clinical development, manufacturing, and IIT clinical results of the company’s lead product, CTA101, a CRISPR-Cas9-engineered off-the-shelf CD19/CD22 dual-targeted CAR T cell product, in R/R B-cell acute Lymphoblastic Leukemia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lemzoparlimab,Pembrolizumab,Rituximab

            Therapeutic Area: Oncology Product Name: TJC4

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            Lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without priming dosing strategy. No dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CT053

            Therapeutic Area: Oncology Product Name: CT053

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Loyal Valley Capital

            Deal Size: $186.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing November 03, 2020

            Details:

            Series C funding will help CARsgen accelerate its ongoing clinical programs and achieve market approval of its leading assets, improving the standard of care in cancers with tremendous unmet medical need.